Shares in PolyNovo (ASX:PNV) are up more than 100% over the last year on the back of the development and commercialisation of the Company’s innovative medical devices using its patented NovoSorb technology. PolyNovo medical devices are used for a number of medical applications and the Company has this year achieved record revenues of the back of sales in the US, Europe, Australia, New Zealand, Asia and the Middle East. Ahead of appearing at the Stocks on Track event in Melbourne, PolyNovo Non-executive Chairman David Williams speaks to Lel Smits on The Stock Network.
1 Unique technology
PolyNovo’s flagship product is a special material called NovoSorb, like a plastic that can safely break down in the body over time, and helps to heal wounds better. Why do you think the industry has embraced this technology
2 Competitive landscape
What’s to stop others trending on your toes in this space?
3 Partnerships, collaborations and innovation
The success of medical technologies often involves strategic partnerships. Can you highlight any key collaborations that have been crucial to PolyNovo’s growth, and are there plans for new partnerships or innovation programs in the near future?
4 Valuation
A share price surge of more than 100% over the last year and has had some ask if you’re overvalued. What is PolyNovo’s strategy to maintain and grow current global sales momentum and which markets do you see as having the most potential for growth?